7th Complement-Based Drug Development Summit

The field of complement-based drug development is experiencing growth due to several factors. Firstly, there is an increasing recognition of the role of the complement system in a wider range of diseases. Additionally, there is a better understanding of the molecular components of the complement system, which has revealed more targets for drug development. Finally, the regulatory landscape is becoming better defined, which is leading to faster approvals for complement-targeting drugs.

The recent approval of SYFOVRE, a C3 inhibitor for geographic atrophy in ophthalmology by Apellis, is a milestone in complement-targeted drug development. Other drug compounds are also being developed and are expected to be approved later in the year, such as those by Iveric Bio.

To bring together experts in the field of immunology and rare diseases and diversify pipelines into complement-mediated autoimmune, neurological, haematological, and nephrological indications, the 7th Complement-Based Drug Development Summit is the conference to attend. With over 150 participants from big pharma, new biotech, and academia, including 25 new speakers, unpublished data, and unshared case studies, this event provides a comprehensive understanding of the field.

The summit covers a range of topics, including target identification, preclinical models, PK/PD evaluation, and clinical outcomes of different drug compounds against the same complement target. This event is a valuable initiative for both non-clinical and clinical complement leads.